Oova: $10.3 Million Raised To Accelerate At-Home Fertility Testing Platform

Oova: $10.3 Million Raised To Accelerate At-Home Fertility Testing Platform Amit Chowdhry

Oova – a company focused on women’s health and fertility solutions – announced a Series A funding round of $10.3 million. The funding round was led by Spero Ventures. Spero Ventures was joined by other strategic firms including US Fertility, Virgin Group, Jefferson Health, Connecticut Innovations, Special Situations Life Sciences Fund, Samsung Next, Hannah Bronfman, and Sara Blakely, the acclaimed businesswoman and founder of Spanx.

The company also announced the new Oova Membership model, which was designed to provide unparalleled support and empowerment to women as they navigate fertility while trying to conceive. Different from traditional one-time purchases or subscription-to-refill kits, the Oova Membership offers a comprehensive, ongoing solution for women’s reproductive health.

Oova founder and CEO Amy Divaraniya, Ph.D., is an expert in biomedical sciences with a focus on genetics. Dr. Divaraniya’s personal struggles to conceive due to an irregular menstrual cycle emphasized the lack of resources women have to access instrumental information about their own bodies, leading Dr. Divaraniya to the development of Oova’s revolutionary technology.

Oova is known as the only test on the market that quantitatively measures luteinizing hormone (LH) and progesterone (PdG) in real time, providing women with daily insights and actionable advice to optimize their chances of conception. And it is FDA registered and the only product that allows its users to sync and share results with their doctor in real time. This innovative approach sets Oova apart, empowering women and their doctors with the knowledge they need to make informed decisions about their reproductive health. The Oova Kit had launched in 2021 and has already trained its model on over 10,000 cycles monitored through the platform.

By understanding the evolving needs of women on their fertility journeys, Oova launched the Oova Membership to address these needs holistically. With a priced of $99 per month, the membership includes The Oova Kit ($159 value) and offers an array of features for women at every step of their fertility journey, including personalized support from Oova’s network of professionals.

The key features of the Oova Membership include:

— Comprehensive Support – The membership grants access to the Oova Provider network, consisting of experienced healthcare professionals and hormone experts.

— Personalized Guidance – Women receive tailored recommendations from hormone experts through consultations.

— Community Connection – The Oova Membership fosters a vibrant and supportive community of like-minded women who are on similar journeys to parenthood. By engaging with this community, members can share their experiences, seek support, and forge valuable connections, creating a sense of camaraderie throughout their fertility journeys.

The launch of the Oova Membership reinforces Oova’s commitment to revolutionizing women’s health and fertility solutions while being a beacon to help them navigate through each stage of their unique journey. With a commitment to being the leading resource for women at the forefront of the femtech industry, the Oova team will continue to introduce access to new products and technology on their mission to address each phase of womanhood; from the beginning of menstruation, on the path to parenthood, and through menopause.

KEY QUOTES:

“Oova has revolutionized the way we understand our hormonal health. By making clinical-grade hormone monitoring convenient and cost-effective for daily use, Oova is empowering its users to understand their cycles, improve fertility outcomes, and manage their symptoms. Simultaneously, Oova offers intricate datasets that provide patients and clinicians an unprecedented objective understanding of how hormones affect our health and well-being. We are honored to be part of the team’s mission to bring these capabilities to women, and to clinical care as a whole.”

— Sara Eshelman, partner at Spero Ventures

“The US Fertility Innovation Fund is proud to partner with and invest in companies with the potential to transform the reproductive space. Oova is poised to do so by providing a more convenient and cost-effective way to measure reproductive hormones at home. Their assays have been rigorously validated and provide accurate results in minutes, allowing them to meet the unique needs of both patients and providers without some of the hurdles of venipuncture.”

— Dr. Eduardo Hariton, Managing Director of US Fertility Innovation Fund

“We recognize that women seeking to start or expand their families desire more than just a test or a tool—they want a comprehensive solution. With the introduction of the Oova Membership, we are excited to provide women with a plan for the next steps in their journey to parenthood. By combining expert guidance, personalized recommendations, and a supportive community, we aim to empower women and ensure they have the tools they need to make informed decisions about their reproductive health.”

— Oova founder and CEO Amy Divaraniya, Ph.D.